metricas
covid
Medicina Clínica (English Edition) Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatme...
Journal Information
Vol. 165. Issue 5.
(November 2025)
Letter to the Editor
Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia”
Respuesta a: “Efectividad de alirocumab y evolocumab (PCSK9i) en el tratamiento de la hipercolesterolemia”
Montserrat Boscha,b,c, Elena Ballarína,c, Immaculada Danésa,b,c,
Corresponding author
immaculada.danes@vallhebron.cat

Corresponding author.
a Clinical Pharmacology Department, Vall d’Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
b Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Clinical Pharmacology Research Group, Vall d’Hebron Institut De Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
Related content
Francisco José Fernández-Fernández, Eugenia Ameneiros-Lago, Alberto Muñiz-Gutiérrez
Article information
Full Text
Bibliography
Download PDF
Statistics

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools